ClinicalTrials.govpublic full text
Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell Carcinoma
clear cell renal cell carcinoma, neoadjuvant therapy, pd-l1, anlotinib, nephron-sparing surgery, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 875654
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.